Drugs Affecting Lipid Metabolism

Front Matter....Pages I-XVI
Relationship of Cholesterol to DNA Synthesis in Normal and Cancerous Cells....Pages 1-8
Turnover of HMG CoA Reductase is Influenced by Phosphorylation....Pages 9-13
Regulation of ACAT....Pages 14-20
Dietary and Pharmacological Control of Cholesterol 7α-Hydroxylase....Pages 21-28
Recent Advances in Metabolic Pathways of Bile Acid Synthesis....Pages 29-33
Bile Acid Sequestrants: Do They Have a Future?....Pages 34-41
Transport of Cholesterol and Cholesterol Esters by HDL....Pages 42-47
Role of HDL in the Metabolism of the Plasma Lipoproteins....Pages 48-51
The Structure of ApoB-100: Structure-Function Studies....Pages 52-55
A Genetic Marker in the Apolipoprotein AI/CIII Gene Complex Associated with Hypercholesterolaemia....Pages 56-58
Cellular and Molecular Biology of Apolipoproteins: Receptor-Mediated Regulation of Cholesterol Metabolism....Pages 59-62
APOA-I and APOA-II Metabolism and Coronary Artery Disease....Pages 63-68
Hypocholesterolemic Drugs and Lipoprotein Metabolism....Pages 69-78
Hypotriglyceridemic Drugs and Lipoprotein Catabolism....Pages 79-82
Lipolysis and Lipoprotein Metabolism....Pages 83-87
Regulation of Lipoprotein Lipase Activity: Its Role in Lipid-Lowering Therapies....Pages 88-93
Lipolysis and Antilipolytic Drugs at Different Ages....Pages 94-97
Fatty Acid-Binding Proteins of Various Tissues....Pages 98-104
Interaction of Lipid-Lowering Drugs with Fatty Acid-Binding Proteins....Pages 105-110
Animal Models for Hyperlipidemia-Induced Atherosclerosis....Pages 111-116
Animal Species as Models of Spontaneous and Induced Hyperlipidemias: A Critical Appraisal....Pages 117-121
Rabbit Models Hypo- or Hyperresponsive to Changes in Diet....Pages 122-125
Plasma Lipoproteins and Cholesterol Metabolism in a Strain of Hyperlipemic Rats....Pages 126-130
Spontaneous Hypertriglyceridemia in a Non-Obese Rat Model: The IVA-SIV Rat....Pages 131-135
Considerations for Controlled Clinical Testing of Safety and Efficacy of New Hypolipidemic Drugs....Pages 136-141
Desirable Lipoprotein Parameters in Early Drug Trials....Pages 142-149
Metabolic Studies with Lovastatin in Patients with Primary Hypercholesteremia....Pages 150-154
Reduction of Plasma Lipids and Lipoproteins by Dietary Fish Oils in Patients with Hypertriglyceridemia....Pages 155-157
Effects of Monounsaturated Fatty Acids Versus Complex Carbohydrates on Serum Lipoprotein Subfractions and Apolipoproteins in Healthy Men and Women....Pages 158-161
Changes of Eicosanoid Formation in Relation to Dietary Lipids and in Hyperlipaemia....Pages 162-166
Effects of Omega-3 Polyunsaturated Fatty Acids on Human Leukocyte Function and Biochemistry....Pages 167-173
Dietary and Biochemical Studies with Textured Soy Proteins....Pages 174-180
Detection of Reactive Free Radicals in Livers of Ethanol-Fed Rats: Potentiating Effect of High Fat Diets....Pages 181-192
The Role of the Antioxidant Tocopherol in Lipid and Lipoprotein Metabolism....Pages 193-196
Newer Aspects of Fats and Lipid Metabolism....Pages 197-199
Can We Retard Atherogenesis by Modifying High-Density Lipoprotein Metabolism?....Pages 200-204
Effects of Lipid-Lowering Drugs on High Density Lipoprotein Structure and Metabolism....Pages 205-209
Enzyme-Inducers and High-Density Lipoproteins....Pages 210-214
Gonadal Steroids and Hormone Antagonists....Pages 215-218
The Effects of Adrenoceptor and Adrenergic Blocking Drugs on Plasma Lipoproteins....Pages 219-222
The Influence of Terpenes and Analogues on Parameters of Atherosclerosis....Pages 223-226
Initial Stages of Reverse Transport of Cholesterol....Pages 227-230
Lipolytic Enzymes and HDL: Influence of Drugs and Hormones....Pages 231-235
Human Apolipoprotein A-I and A-II Metabolism....Pages 236-243
Roles of LCAT and Lipid Transfer Protein in HDL Metabolism....Pages 244-246
The Profile of an HMG-CoA Reductase Inhibitor, CS-514 (SQ 31,000)....Pages 247-250
Induction of Hepatic Low-Density Lipoprotein Receptors in Heterozygous WHHL Rabbits Treated with CS-514 Alone or CS-514 in Combination with Cholestyramine....Pages 251-254
The Clinical Pharmacology of SQ 31,000 (CS 514) in Healthy Subjects....Pages 255-259
Long-Term Effects of CS-514 on Serum Lipoprotein Lipid and Apolipoprotein Levels in Patients with Familial Hypercholesterolemia....Pages 260-268
Intensive Drug Treatment for Familial Hypercholesterolemia....Pages 269-273
Effect of CS-514 on Hypercholesterolemic Patients....Pages 274-277
Hyperlipoproteinemia and Therapy: Results of a Multicenter Trial with Bezafibrate, a New Lipid-Lowering Drug....Pages 278-282
Lipoprotein Changes Induced by Bezafibrate — 200 mg t. i. d. — and by Bezafibrate in a Slow-Release Preparation — 400 mg Once a Day — in Patients with Primary Hyperlipoproteinaemia....Pages 283-290
Modifications of Apoprotein, Lipoprotein Parameters and HDL 2 and HDL 3 Subfractions During Treatment with Bezafibrate Retard....Pages 291-294
Effect of Bezafibrate Retard on Plasma Lipoproteins in Hypertriglyceridemic Patients With and Without Diabetes Mellitus....Pages 295-300
Long-Term Experience of a Single Daily Dose of Bezafibrate Retard 400 in Hyperlipoproteinaemia of Types IIa, IIb, and IV....Pages 301-304
Effects of Bezafibrate on Lipoprotein Metabolism in Cell Culture....Pages 305-308
Efficacy and Tolerance of Fenofibrate: A Ten-Year Experience....Pages 309-316
Mechanism of Action of Fenofibrate: New Data....Pages 317-323
Species Differences in the Metabolic Disposition of Fenofibrate....Pages 324-327
Pharmacokinetics of Lipanthyl in the Elderly....Pages 328-332
Effect of Fenofibrate on Lipoprotein Particles Predictive of Coronary Atherosclerosis....Pages 333-337
Tentative Biochemical Approach to Fenofibrate Efficacy in Tinnitus Aurium....Pages 338-342
Clinical Effect of Lipanthyl on Tinnitus Aurium and Other Symptoms Related to Inner Ear Disorders....Pages 343-349
Effect of Gemfibrozil Administration on Biliary Lipid Secretion: A Crossover Study with Clofibrate....Pages 350-354
Plasma Lipids, Lipoproteins, and Apoproteins During Gemfibrozil Treatment in Primary Hyperlipidemias....Pages 355-357
Effects of Gemfibrozil on Lipoproteins in Patients with Dyslipoproteinemia....Pages 358-366
HDL Deficiency, Atherosclerosis, and Stimulation of HDL Synthesis: Role of Gemfibrozil....Pages 367-371
Hemorheological Activity of Gemfibrozil in Primary Hyperlipidemias....Pages 372-375
Evaluation of Hypolipidemic and Other Useful Pharmacological Properties of Various Nicotinic Acid Derivatives....Pages 376-379
Pharmacokinetics and Metabolism of 2-Tert-Butyl-4-Cyclohexyl-Phenyl Nicotinate (L-44) in Rats....Pages 380-384
Effects of Etofibrate on Risk Factors of Atherosclerosis....Pages 385-388
Hyperaggregability of Platelets in Patients with Hyperlipoproteinemia Type IIb Under Treatment with Etofibrate Retard and Acetylsalicylic Acid....Pages 389-393
Effect of Etofibrate on Platelet Function in Hyperlipidemic Patients....Pages 394-398
Importance of Phospholipids in Cholesterol-Solubilizing Capacity of High-Density Lipoproteins....Pages 399-402
Effects of Polyunsaturated Phospholipid on Cholesterol Efflux in Vitro and in Experimental Animals and Human Subjects....Pages 403-406
Phospholipids in Human Atherosclerosis....Pages 407-409
Effect of Polyunsaturated Phosphatidylcholine (PPC) on Plasma Lipoproteins in Patients with Type II Hyperlipoproteinemia....Pages 410-414
Dietary Lecithin: Metabolism, Fate, and Effects on Metabolism of Lipids and Lipoproteins....Pages 415-420
Effects of Pantethine on Lipid Metabolism in Isolated Rat Hepatocytes....Pages 421-425
Effects of Pantethine on Experimental Atherosclerosis in Rabbits....Pages 426-432
Modified LDL in Humans: Effect of Pantethine....Pages 433-436
Changes in Platelet Membrane Lipid Composition Following Pantethine Administration....Pages 437-441
Pantethine Treatment in Type III Hyperlipoproteinemia....Pages 442-446
Back Matter....Pages 447-451